About Firefly Bio
Firefly Bio is a company based in San Francisco (United States) founded in 2022 by John Flygare, Carolyn Bertozzi, and Bernhard Geierstanger.. Firefly Bio has raised $94 million across 3 funding rounds from investors including Lilly, HHS and Versant Ventures. Firefly Bio offers products and services including Degrader Antibody Conjugates and Proprietary Platform. Firefly Bio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Founders John Flygare, Carolyn Bertozzi, Bernhard Geierstanger
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Firefly Bio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$94 M (USD)
in 3 rounds
-
Latest Funding Round
$94 M (USD), Series A
Dec 18, 2023
-
Investors
Lilly
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Firefly Bio
Firefly Bio offers a comprehensive portfolio of products and services, including Degrader Antibody Conjugates and Proprietary Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Combines ADCs with protein degraders for targeted tissue delivery.
Enables scalable production and delivery of ADC payloads.
Unlock access to complete
Unlock access to complete
Funding Insights of Firefly Bio
Firefly Bio has successfully raised a total of $94M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $94 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $94.0M
-
First Round
First Round
(05 Mar 2022)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series A - Firefly Bio | Valuation | Versant Ventures , MPM Capital | |
| Sep, 2022 | Amount | Grant - Firefly Bio | Valuation |
investors |
|
| Mar, 2022 | Amount | Grant - Firefly Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Firefly Bio
Firefly Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, HHS and Versant Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science and technology sectors
|
Founded Year | Domain | Location | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Firefly Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Firefly Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Firefly Bio Comparisons
Competitors of Firefly Bio
Firefly Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Firefly Bio
Frequently Asked Questions about Firefly Bio
When was Firefly Bio founded?
Firefly Bio was founded in 2022.
Where is Firefly Bio located?
Firefly Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Firefly Bio?
Scott Hirsch is the current CEO of Firefly Bio.
Is Firefly Bio a funded company?
Firefly Bio is a funded company, having raised a total of $94M across 3 funding rounds to date. The company's 1st funding round was a Grant of $176.4K, raised on Mar 05, 2022.
What does Firefly Bio do?
Developer of antibody drug conjugates for the treatment of cancer. The company uses potent catalytic protein degraders as the payloads of ADCs to develop class of therapeutics for a range of intracellular biological targets such as both solid and liquid tumors.
Who are the top competitors of Firefly Bio?
Firefly Bio's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does Firefly Bio offer?
Firefly Bio offers Degrader Antibody Conjugates and Proprietary Platform.
Who are Firefly Bio's investors?
Firefly Bio has 5 investors. Key investors include Lilly, HHS, Versant Ventures, Turmeric Acquisition Corp, and Decheng Capital.